- IDEAYA Biosciences (IDYA, Financial) has granted stock options for 185,400 shares to four new employees.
- Options have a 10-year term with a vesting schedule over four years.
- The exercise price is set at $19.07 per share, matching the closing market price on the grant date.
On April 24, 2025, IDEAYA Biosciences, Inc. (IDYA), an innovative company in precision medicine oncology, announced the approval of non-qualified stock options for four newly hired employees as part of their 2023 Employment Inducement Incentive Award Plan. The options collectively cover 185,400 shares of common stock, priced at $19.07 per share, aligning with the stock's closing price on the Nasdaq Global Select Market at the time of grant.
These inducement grants, authorized under Nasdaq Listing Rule 5635(c)(4), are structured with a 10-year term. The vesting schedule is designed to motivate long-term commitment, with 25% of the options vesting after the first year and the remaining 75% vesting over three years in monthly installments, contingent on the continued service of the employees with the company.
The Inducement Plan is aimed at attracting new talent by offering equity compensation, providing an initial step for employees who have not previously been part of IDEAYA. This strategy highlights IDEAYA's commitment to leveraging equity as a means of aligning employee interests with those of shareholders, while also potentially leading to future dilution from the issuance of new stock options.
